{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Baden LR"],"funding":["NCATS NIH HHS","NIAID NIH HHS"],"pagination":["313-22"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5034222"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["164(5)"],"pubmed_abstract":["<h4>Background</h4>A prophylactic HIV-1 vaccine is a global health priority.<h4>Objective</h4>To assess a novel vaccine platform as a prophylactic HIV-1 regimen.<h4>Design</h4>Randomized, double-blind, placebo-controlled trial. Both participants and study personnel were blinded to treatment allocation. (ClinicalTrials.gov: NCT01215149).<h4>Setting</h4>United States, East Africa, and South Africa.<h4>Patients</h4>Healthy adults without HIV infection.<h4>Intervention</h4>2 HIV-1 vaccines (adenovirus serotype 26 with an HIV-1 envelope A insert [Ad26.EnvA] and adenovirus serotype 35 with an HIV-1 envelope A insert [Ad35.Env], both administered at a dose of 5 × 1010 viral particles) in homologous and heterologous combinations.<h4>Measurements</h4>Safety and immunogenicity and the effect of base"],"journal":["Annals of internal medicine"],"pubmed_title":["Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial."],"pmcid":["PMC5034222"],"funding_grant_id":["UM1 AI069412","UM1 AI068614","U19 AI066305","UM1 AI068618","UL1 TR000170","UM1 AI069453"],"pubmed_authors":["Hayes P","Swann E","Innes C","Page-Shipp L","Grazia-Pau M","Karita E","Peter L","Anzala O","Dolin R","Sadoff J","Laher F","Laufer DS","B003-IPCAVD004-HVTN091 Study Group","Seaman MS","Gilmour J","Walsh SR","McElrath MJ","Mutua G","Cohen YZ","Barouch DH","Baden LR","Weijtens M","Grunenberg N","Frahm N","Fast P","Lombardo A","Nyombayire J","Cox J","Roux S","Gray G","McElrath M","Dally L","Bekker LG"],"additional_accession":[]},"is_claimable":false,"name":"Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.","description":"<h4>Background</h4>A prophylactic HIV-1 vaccine is a global health priority.<h4>Objective</h4>To assess a novel vaccine platform as a prophylactic HIV-1 regimen.<h4>Design</h4>Randomized, double-blind, placebo-controlled trial. Both participants and study personnel were blinded to treatment allocation. (ClinicalTrials.gov: NCT01215149).<h4>Setting</h4>United States, East Africa, and South Africa.<h4>Patients</h4>Healthy adults without HIV infection.<h4>Intervention</h4>2 HIV-1 vaccines (adenovirus serotype 26 with an HIV-1 envelope A insert [Ad26.EnvA] and adenovirus serotype 35 with an HIV-1 envelope A insert [Ad35.Env], both administered at a dose of 5 × 1010 viral particles) in homologous and heterologous combinations.<h4>Measurements</h4>Safety and immunogenicity and the effect of base","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Mar","modification":"2026-05-01T18:04:46.003Z","creation":"2026-04-07T17:10:03.701Z"},"accession":"S-EPMC5034222","cross_references":{"pubmed":["26833336"],"doi":["10.7326/M15-0880","10.7326/m15-0880"]}}